News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
Color researchers reported that 21.7 percent of individuals with pathogenic variants in well-established genes did not meet guidelines for testing.
The two genome-wide scores to predict coronary artery disease risk, which were developed using UK Biobank data, were also valid in French-Canadians.
Akonni has received clearance for a molecular diagnostic instrument and a saliva-based pharmacogenomics test for warfarin metabolism.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
The facility will be mass spec-focused and comprise a service contract lab for developing protein tests and a CAP- and CLIA-certified lab for offering them.
